Active substanceLizinopril + HydrochlorothiazideLizinopril + Hydrochlorothiazide
Similar drugsTo uncover
  • Co-Diroton
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Lisinopril H STADA
    pills inwards 
    NIZHFARM, JSC     Russia
  • Lysinoton H
    pills inwards 
  • Lizoretik®
    pills inwards 
  • Rileys-Sanovel plus
    pills inwards 
  • Skopril plus
    pills inwards 
    Alkaloid, JSC     Macedonia
  • Dosage form: & nbsppills
    Composition:

    1 tablet of 10 mg + 12.5 mg contains:

    active substances: lisinopril dihydrate 10.89 mg (corresponding to lisinopril 10 mg) and hydrochlorothiazide 12.5 mg;

    Excipients: Mannitol 18.7 mg, calcium hydrophosphate dihydrate 57,14 mg, corn pregelatinized corn starch 4 mg, dye 1.6 mg (corn starch pregelatinized starch 1,488 mg, iron oxide yellow (E 172) 0.08 mg, iron oxide red (E 172) 0.032 mg), croscarmellose sodium 4.4 mg, magnesium stearate 0.77 mg.

    1 tablet of 20 mg + 12.5 mg contains:

    active substances: lisinopril dihydrate 21.78 mg (corresponding to lisinopril 20 mg) and hydrochlorothiazide 12.5 mg;

    Excipients: mannitol 38.3 mg, calcium hydrophosphate dihydrate 117.05 mg, corn pregelatinized starch 10.5 mg, croscarmellose sodium 8.4 mg, magnesium stearate 1.47 mg.

    1 tablet of 20 mg + 25 mg contains:

    active substances: lisinopril dihydrate 21.78 mg (corresponding to lisinopril 20 mg) and hydrochlorothiazide 25 mg;

    Excipients: mannitol 37.4 mg, calcium hydrogen phosphate dihydrate 114.28 mg, starch corn pregelatinized 8 mg, dye 3.2 mg (corn starch pregelatinized starch 2.976 mg, iron oxide yellow (E 172) 0.16 mg, iron oxide red (E 172) 0.064 mg), croscarmellose sodium 8.8 mg, magnesium stearate 1.54 mg.

    Description:Round, biconvex tablets labeled "LH" on the one hand. Tablets with a dosage of 10 mg + 12.5 mg yellow-orange color, without a notch. Tablets of 20 mg + 12.5 mg of white color with a notch on one side. Tablets with a dosage of 20 mg + 25 mg - yellow-orange color with a notch on one side. Presence of marble is admissible.
    Pharmacotherapeutic group:Hypotensive combined agent (angiotensin-converting enzyme inhibitor + diuretic)
    ATX: & nbsp

    C.09.B.A.03   Lizinopril in combination with diuretics

    Pharmacodynamics:

    Lysinoton H is a combination of an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) and a diuretic (hydrochlorothiazide). Has antihypertensive and diuretic effect.

    Lysinopril. ACE inhibitor, reduces the formation of angiotensin II from angiotensin I.Reduction of angiotensin II leads to a direct decrease in the release of aldosterone. Reduces the degradation of bradykinin and increases the synthesis of prostaglandins. Reduces the overall peripheral vascular resistance, arterial pressure (BP), preload, pressure in the pulmonary capillaries, causes an increase in the minute volume of blood and increased tolerance to stress in patients with heart failure. Expands arteries more than veins. Some effects are explained by the effect on tissue renin-angiotensin systems. With prolonged use, myocardial hypertrophy and the walls of arteries of resistive type decrease. Improves the blood supply of the ischemic myocardium. ACE inhibitors prolong life expectancy in patients with chronic heart failure, slow the progression of left ventricular dysfunction in patients who underwent myocardial infarction without clinical manifestations of heart failure. The beginning of the action after 1 hour, the maximum effect is determined after 6-7 hours, duration - 24 hours. With arterial hypertension, the effect is observed in the first days after the start of treatment, stable action develops after 1-2 months.

    Hydrochlorothiazide. A thiazide diuretic whose diuretic effect is associated with a disruption of the reabsorption of sodium, chlorine, potassium, magnesium, water in the distal nephron; delays the excretion of calcium ions, uric acid. Has antihypertensive effect, which develops due to the expansion of arterioles. Virtually no effect on normal blood pressure. Diuretic effect occurs in 1-2 hours, reaches a maximum after 4 hours and lasts 6-12 hours. Antihypertensive effect occurs in 3-4 days, but it may take 3-4 weeks to achieve the optimal therapeutic effect.

    Lizinopril and hydrochlorothiazide, if used simultaneously, have an additive antihypertensive effect.

    Pharmacokinetics:

    Lisinopril

    After taking the drug inside lisinopril is absorbed from the gastrointestinal tract (GIT). Eating does not affect the absorption of the drug. Absorption averages 30%.

    Almost does not bind to plasma proteins. The maximum concentration in blood plasma (90 ng / ml) is reached after approximately 7 hours (TCmax). Permeability through the blood-brain and placental barrier is low. Lisinopril not biotransformed in the body.

    It is excreted by the kidneys unchanged. Half-life (T1/2) is 12 hours.

    Hydrochlorothiazide

    After ingestion, hydrochlorothiazide is rapidly absorbed. Bioavailability is 60-80%. ТСmах - 2-5 hours. Communication with blood plasma proteins - 60-80%. Penetrates through the hematoplacental barrier and into breast milk. T1/2 - 6-15 hours. It is not metabolized by the liver. It is excreted by the kidneys: more than 95% of the dose in unchanged form and about 4% in the form of hydrolyzate-2-amino-4-chloro-m-benzene disulfonamide.

    Indications:Arterial hypertension (in patients who are shown combined therapy).
    Contraindications:

    - Hypersensitivity to the active and auxiliary substances of the drug, other ACE inhibitors and derivatives of sulfonylamides;

    - angioedema in history after use of ACE inhibitors;

    - hereditary or idiopathic angioedema;

    - marked renal failure (creatinine clearance (CK) less than 30 ml / min);

    - anuria;

    - severe liver dysfunction;

    - hemodialysis using high-flow membranes;

    - age to 18 years (efficacy and safety not established).

    Carefully:Aortic stenosis / hypertrophic cardiomyopathy, bilateral renal artery stenosis, stenosis of the artery only kidneys with progressive azotemia, condition after kidney transplantation, renal failure (creatinine clearance of more than 30 and less than 80 ml / min), primary hyperaldosteronism, hypotension, marrow hypoplasia, hyponatremia ( an increased risk of hypotension in patients who are at malosolevoy or salt-free diet); conditions, accompanied by a decrease in the volume of circulating blood (including diarrhea, vomiting); connective tissue disease (systemic lupus erythematosus, scleroderma), diabetes, gout, hyperuricemia, hyperkalemia, coronary heart disease, cerebrovascular disease, severe chronic heart failure, liver failure, old age.
    Pregnancy and lactation:

    Pregnancy

    ACE inhibitors during the first trimester of pregnancy is not recommended and is contraindicated during the second and third trimesters of pregnancy.

    Epidemiological studies have not confirmed the risk of developing teratogenic effects afterreception of ACE inhibitors during the first trimester of pregnancy, in spite of this, this risk can not be completely eliminated. If it is necessary to continue antihypertensive therapy, the patient planning a pregnancy should be given alternative treatment with drugs that have a known safety profile during admission during pregnancy. In case of pregnancy, immediately stop taking ACE inhibitors and, if possible, start therapy with alternative drugs.

    Application during pregnancy requires careful individual assessment of the risk-benefit relationship for the patient and fetus.

    Lactation

    During the treatment, the drug should be abolished breastfeeding.

    Dosing and Administration:

    Take inside, once a day, at about the same time.

    Essential hypertension

    1 tablet Lysinoton H 10 mg + 12.5 mg once a day. If necessary, the dose of the drug can be increased to 20 mg + 12.5 mg once a day. The maximum daily dose of a combination of lisinopril / hydrochlorothiazide is 40/25 mg.

    Doses in renal failure

    In patients with SC greater than 30 and less than 80 ml / min, Lysinoton H can be used only after titrating the dose of individual components of the drug. The recommended initial dose lisinopril and in this case is 5-10 mg.

    Elderly age

    Age does not affect the efficacy and tolerability of the combination

    lisinopril / hydrochlorothiazide.

    Prior therapy with diuretics

    Symptomatic hypotension can occur after taking the initial dose of the drug. Such cases are more common in patients with fluid loss and electrolytes due to previous treatment with diuretics. Therefore, the use of diuretics should be stopped 2-3 days before the start of treatment with the drug.

    Side effects:

    In most patients, side effects were mild and transient and in most cases did not require therapy.

    The most frequent were: dizziness and headache.

    From the organs of hematopoiesis and lymphatic system: reduction of hemoglobin and hematocrit, oppression of bone marrow function, anemia, thrombocytopenia, leukopenia, neutropenia, agranulocytosis, hemolytic anemia, lymphadenopathy, autoimmune disease.

    From the side of metabolism and nutrition: hypoglycemia.

    Disorders from the psyche: mood lability, depressive symptoms, impaired concentration.

    Impaired nervous system: dizziness, headache, syncope, paresthesia, vertigo, taste disorder, sleep disturbance.

    Heart Disease: myocardial infarction, possibly secondary, arisen against arterial hypotension in patients with risk factors; palpitation, tachycardia.

    Vascular disorders: orthostatic effects, including orthostatic hypotension, Raynaud's syndrome.

    Disturbances from the respiratory system, chest and mediastinal organs: dry cough, bronchospasm.

    Disorders from the digestive tract: diarrhea, vomiting; nausea, abdominal pain and digestive disorders, dryness of the oral mucosa, pancreatitis.

    Disorders from the liver and bile ducts: increased concentration of "hepatic" enzymes and bilirubin in the blood; hepatitis, including hepatocellular or cholestatic, jaundice.

    From the skin and subcutaneous tissues: skin rashes, itching, angioedema, swelling of the face, extremities, lips, tongue, vocal cords and / or larynx; urticaria, hair loss.

    Disorders from the kidneys and urinary tract: impaired renal function, uremia, acute renal failure, oliguria / anuria.

    Violations of the genitals and breast: gynecomastia.

    General disorders and disorders at the site of administration: asthenia, fatigue.

    Laboratory and instrumental data: increase in urea concentration and creatinine, hyperkalemia; hyponatremia.

    Overdose:

    Overdose Symptoms: marked decrease in blood pressure.

    Treatment: induce vomiting and / or rinse the stomach, symptomatic therapy aimed at correcting dehydration and disturbances of the water-salt balance. When arterial hypotension is introduced isotonic solution. Control of urea, creatinine and electrolytes in blood serum, as well as diuresis.

    Interaction:Lithium

    With simultaneous administration of ACE inhibitors and lithium, a reversible increase in the concentration of lithium in the blood plasma and an increase in its toxic effects (increased cardiotoxic and neurotoxic effects of lithium) were observed.

    Potassium-sparing diuretics, potassium preparations, salt substitutes, containing potassium

    The excretion of potassium with thiazide diuretics is usually weakened by the potassium-sparing effect of lisinopril. The use of potassium-sparing diuretics, potassium preparations, salt substitutes,containing potassium in patients with impaired renal function or diabetes mellitus can lead to a marked increase in potassium concentration in the blood. Together with the drug should be taken with caution potassium-sparing diuretics, potassium preparations, salt substitutes, containing potassium, and regularly monitor the level of potassium in the blood serum.

    Tricyclic antidepressants / antipsychotics / anesthetics

    Simultaneous reception with tricyclic antidepressants, antipsychotics and anesthetics can increase the antihypertensive effect.

    Non-steroidal anti-inflammatory drugs (NSAIDs) / antirheumatoid agents

    Prolonged use of NSAIDs (selective inhibitors of COX-2, acetylsalicylic acid> 3 g / day and nonselective NSAIDs) can reduce the antihypertensive effect of ACE inhibitors and the antidiuretic effect of thiazide diuretics. Simultaneous administration of NSAIDs and ACE inhibitors has an additive effect on the increase in potassium concentration in the serum, which can lead to impaired renal function. This effect, as a rule, is reversible. In rare cases, acute renal failure may occur, especially in patients with impaired renal function (elderly patients, lack of fluid in the body).

    Gold

    Very often after injections of a gold preparation (for example, sodium aurotomy malate) in patients taking ACE inhibitors, nitrite reactions were reported (symptoms of vasodilation, including flushing to the face, nausea, dizziness, marked decrease in blood pressure).

    Sympathomimetics

    Sympathomimetics can reduce the antihypertensive effect of ACE inhibitors.

    Other antihypertensive drugs

    Simultaneous reception of these agents can enhance the antihypertensive effect of the combination lisinopril / hydrochlorothiazide. Simultaneous intake of nitroglycerin and other nitrates, as well as other vasodilating agents, may enhance the antihypertensive effect.

    Salts of calcium

    Simultaneous reception of thiazide diuretics can increase the concentration of calcium in the blood serum due to a decrease in its excretion.

    Cardiac glycosides

    With simultaneous admission with thiazide diuretics, the risk of hypokalemia increases, which increases the possibility of cardiotoxic effects.

    Kolestyramine and colestipol

    These substances can reduce the absorption of hydrochlorothiazide. Therefore, sulfonylamide diuretics should be taken at least 1 hour before or 4-6 hours after taking colestyramine and colestipol.

    Non-depolarizing muscle relaxants (eg, tubocurarine chloride)

    The effect of this group of drugs may be enhanced by joint admission hydrochlorothiazide.

    Trimethoprim

    Joint administration of ACE inhibitors and thiazide diuretics with trimethoprim increases the risk of hyperkalemia.

    Cytotoxic drugs, immunosuppressants, procainamide

    Simultaneous administration of ACE inhibitors with this group of drugs increases the risk of developing leukopenia (see Special instructions).

    Special instructions:

    Symptomatic hypotension

    In rare cases, symptomatic hypotension occurs in patients with arterial hypertension. Most often, a marked decrease in blood pressure occurs with a decrease in the volume of circulating blood caused by diuretic therapy, limiting the amount of salt in the food, dialysis, diarrhea, vomiting, or in patients with severe renin-induced arterial hypertension. This group of patients should regularly monitor the level of electrolytes in the blood serum. In patients who have risk factors for symptomatic hypotension, it is necessary to begin treatment and adjust the dose under the strict supervision of a physician.Similar rules should be adhered to when prescribing a drug for patients with coronary heart disease and cerebrovascular insufficiency, in which a sharp decrease in blood pressure can lead to myocardial infarction or stroke.

    In the case of the development of severe arterial hypotension, the patient should assume the position of "lying" on the back, and, if necessary, initiate an intravenous injection of isotonic solution. A short-term reduction in blood pressure is not a contraindication for taking the next dose of Lysinoton N. The drug may be taken after a dose reduction after the recovery of circulating blood and the normalization of blood pressure. It is also possible to take the components of the drug (lisinopril and hydrochlorothiazide) separately. Like other vasodilators, Lisotonon H should be taken with caution in patients with aortic stenosis or hypertrophic cardiomyopathy.

    Impaired renal function

    Thiazide diuretics are not indicated for admission to patients with impaired renal function and may be ineffective in CC less than 30 mL / min.

    In patients with bilateral stenosis of the renal arteries or stenosis of the artery of a single kidney treated with ACE inhibitors, there was an increase in urea and serum creatinine, usually reversible after discontinuation of treatment. It was more common in patients with renal insufficiency.

    Kidney Transplantation

    There is no experience of using the drug in patients with recent kidney transplantation, so it is recommended that this group of patients be taken with caution.

    Anaphylactoid reactions and patients on hemodialysis and apheresis of low-density lipoproteins

    Preparations containing lisinopril, are not indicated for use in patients requiring dialysis in view of renal insufficiency.

    In patients on hemodialysis (eg, using dialysis membranes with high permeability AN 69 and with the apheresis of low-density lipoproteins with dextran-sulfate absorption), which simultaneously take ACE inhibitors, anaphylactoid reactions are noted. In such cases, one should consider the possibility of using another type of membrane for dialysis or another antihypertensive agent.

    Surgery / general anesthesia

    With the use of agents that reduce blood pressure in patients with extensive surgery or during general anesthesia, lisinopril can block the formation of angiotensin II.

    The pronounced decrease in blood pressure, which is considered a consequence of this mechanism, can be eliminated by increasing the volume of circulating blood.

    Before surgery (including dentistry), it is necessary to alert the surgeon / anesthesiologist about the use of ACE inhibitors.

    Metabolic and endocrine effects

    Thiazide diuretics can influence glucose tolerance, so you need to adjust the dose of funds for the treatment of diabetes. In patients with diabetes mellitus and taking antidiabetic oral drugs and insulin, the blood glucose concentration should be monitored regularly during the first month of treatment with ACE inhibitors. In people with latent diabetes mellitus during treatment with thiazide diuretics, clinical signs of diabetes mellitus may appear.

    Therapy with thiazide diuretics can cause hyperuricemia and / or gout in some patients. In the same time lisinopril can increase the urea content in the urine and thereby weaken the hyperuricemic effect of hydrochlorothiazide.

    Violation of electrolyte balance

    Every patient receiving diuretics should periodically monitor the concentration of electrolytes in the blood serum.

    Hydrochlorothiazide can cause a change in the volume of circulating blood and disturb the electrolyte balance (hypokalemia, hyponatremia and hypochloraemia). Signs of lack of fluid in the body and electrolyte imbalance are the following: dryness in the mouth, thirst, fatigue, lethargy, drowsiness, muscle aches or cramps, muscle fatigue, arterial hypotension, oliguria, tachycardia, gastrointestinal disorders (nausea or vomiting).

    Thiazide diuretics can reduce the excretion of calcium in the urine and cause a slight increase in calcium in the serum. Expressed hypercalcemia may be a symptom of latent hyperparathyroidism, it is recommended that treatment with thiazide diuretics be stopped before the parathyroid function test.

    Hypersensitivity / angioedema

    In rare cases, patients taking ACE inhibitors, including lisinopril, angioedema of the face, limbs, lips, tongue, epiglottis and / or larynx was noted (can occur during any treatment period). In this case, the treatment with lisinopril should be stopped immediately, and the patient should be monitored until the symptoms regress completely. Even in cases where the swelling only covers the tongue, without disrupting the airway patency, the patient may need long-term follow-up, since therapy with antihistamines and glucocorticosteroids may not be sufficient.

    Neutropenia / agranulocytosis

    In the course of treatment with ACE inhibitors, neutropenia / agranulocytosis, thrombocytopenia and anemia were reported. In patients with normal renal function without other risk factors, neutropenia occurred in very rare cases. Neutropenia and agranulocytosis were reversible and passed after discontinuation of ACE inhibitors.

    During the period of treatment, it is not recommended to drink alcoholic beverages, since alcohol increases the antihypertensive effect of the drug.

    Care should be taken when doing physical exercises, hot weather (the risk of dehydration and excessive blood pressure lowering due to a decrease in the volume of circulating blood).

    Effect on the ability to drive transp. cf. and fur:During the period of treatment, one should refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions, since dizziness is possible, especially at the beginning of the course of treatment and when correcting the dose.
    Form release / dosage:Tablets 10 / 12.5 mg, 20 / 12.5 mg, 20/25 mg.
    Packaging:7, 10, 14 tablets in a blister of PVDC / aluminum foil. 1 or 3 blisters (10 tablets each), 2 or 4 blisters (7 tablets each), 1 or 2 blisters (14 tablets each), along with instructions in a cardboard box. For 10, 20, 40, 60 blisters together with instructions for use in a cardboard box (for hospitals).
    Storage conditions:Do not store at temperatures above 30 ° C. Keep out of the reach of children!
    Shelf life:3 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-001898
    Date of registration:11.08.2011 / 05.10.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:Actavis PTS ehf GroupActavis PTS ehf Group Iceland
    Manufacturer: & nbsp
    Representation: & nbspAktavis, Open Company Aktavis, Open Company
    Information update date: & nbsp24.02.2018
    Illustrated instructions
      Instructions
      Up